Childhood acute lymphoblastic leukemia: Progress through collaboration

Journal of Clinical Oncology

Volumn 33, Issue 27, 2015, Pages 2938-2948

  Pui, Ching Hon ^a   Yang, Jun J ^a   Hunger, Stephen P ^b   Pieters, Rob ^c   Schrappe, Martin ^d   Biondi, Andrea ^f   Vora, Ajay ^g   Baruchel, André ^h   Silverman, Lewis B ⁱ   Schmiegelow, Kjeld ^j   Escherich, Gabriele ^e   Horibe, Keizo ^k   Benoit, Yves C M ^l   Izraeli, Shai ^m   Yeoh, Allen Eng Juh ⁿ   Liang, Der Cherng ^o   Downing, James R ^a   Evans, William E ^a   Relling, Mary V ^a   Mullighan, Charles G ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c University Medical Center Utrecht Princess Máxima Center for Pediatric Oncology   (Netherlands)

^d UNIVERSITY OF KIEL   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY OF MILANO BICOCCA   (Italy)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h HÔPITAL ROBERT DEBRÉ   (France)

ⁱ BOSTON CHILDREN S HOSPITAL   (United States)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

^k NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^l GHENT UNIVERSITY   (Belgium)

^m SHEBA MEDICAL CENTER   (Israel)

ⁿ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^o MACKAY MEMORIAL HOSPITAL   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER SUSCEPTIBILITY; CHILDHOOD LEUKEMIA; CHROMOSOME 11Q; CHROMOSOME REARRANGEMENT; DOWN SYNDROME; DRUG TOXICITY; DRUG TREATMENT FAILURE; ETHNIC DIFFERENCE; EVENT FREE SURVIVAL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMOGENESIS; LEUKOCYTE COUNT; LONG TERM SURVIVAL; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRE T LYMPHOCYTE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; ADOLESCENT; CHILD; COOPERATION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HISTORY; INFANT; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; MASS COMMUNICATION; MORTALITY; NEWBORN; ONCOLOGY; ONSET AGE; PEDIATRICS; PERSONALIZED MEDICINE; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE; PRESCHOOL CHILD; SURVIVOR; TIME; TRENDS;

ADOLESCENT; AGE OF ONSET; BIOMARKERS, TUMOR; CHILD; CHILD, PRESCHOOL; COOPERATIVE BEHAVIOR; DIFFUSION OF INNOVATION; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFANT; INFANT, NEWBORN; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; MEDICAL ONCOLOGY; PEDIATRICS; PHENOTYPE; PRECISION MEDICINE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84942233197     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.1636     Document Type: Review

References (101)

1. Conter V, Aricò M, Basso G, et al: Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 24:255-264, 2010
2. Möricke A, Zimmermann M, Reiter A, et al: Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 24:265-284, 2010
3. Escherich G, Horstmann MA, Zimmermann M, et al: Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): Long-term results of trials 82, 85, 89, 92 and 97. Leukemia 24:298-308, 2010
4. Hunger SP, Lu X, Devidas M, et al: Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the Children's Oncology Group. J Clin Oncol 30:1663-1669, 2012
5. Veerman AJ, Kamps WA, van den Berg H, et al: Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: Results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 10:957- 966, 2009
6. Vrooman LM, Stevenson KE, Supko JG, et al: Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: Results from a randomized study - Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 31:1202-1210, 2013
7. Domenech C, Suciu S, De Moerloose B, et al: Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica 99:1220-1227, 2014
8. Stary J, Zimmermann M, Campbell M, et al: Intensive chemotherapy for childhood acute lymphoblastic leukemia: Results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol 32:174-184, 2014
9. Yamaji K, Okamoto T, Yokota S, et al: Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: A report from the Japanese Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer 55:1287-1295, 2010
10. Yeoh AE, Ariffin H, Chai EL, et al: Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: Results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol 30:2384- 2392, 2012
11. Vora A, Goulden N, Mitchell C, et al: Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): A randomised controlled trial. Lancet Oncol 15:809-818, 2014
12. Schmiegelow K, Forestier E, Hellebostad M, et al: Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 24:345-354, 2010
13. Pui CH, Pei D, Campana D, et al: A revised definition for cure of childhood acute lymphoblastic leukemia. Leukemia 28:2336-2343, 2014
14. Liu HC, Yeh TC, Hou JY, et al: Triple intrathecal therapy alone with omission of cranial radiation in children with acute lymphoblastic leukemia. J Clin Oncol 32:1825-1829, 2014
15. Downing JR, Wilson RK, Zhang J, et al: The Pediatric Cancer Genome Project. Nat Genet 44: 619-622, 2012
16. Pui CH, Schrappe M, Masera G, et al: Ponte di Legno Working Group: Statement on the right of children with leukemia to have full access to essential treatment and report on the Sixth International Childhood Acute Lymphoblastic Leukemia Workshop. Leukemia 18:1043-1053, 2004
17. Hunger SP, Baruchel A, Biondi A, et al: The thirteenth international childhood acute lymphoblastic leukemia workshop report: La Jolla, CA, USA, December 7-9, 2011. Pediatr Blood Cancer 60:344- 348, 2013
18. Schrappe M, Nachman J, Hunger S, et al: 'Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985-2000)'. Leukemia 24: 253-254, 2010
19. Conter V, Bartram CR, Valsecchi MG, et al: Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115:3206-3214, 2010
20. Schrappe M, Valsecchi MG, Bartram CR, et al: Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study. Blood 118:2077-2084, 2011
21. Pieters R, Schrappe M, De Lorenzo P, et al: A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): An observational study and a multicentre randomised trial. Lancet 370:240-250, 2007
22. Mann G, Attarbaschi A, Schrappe M, et al: Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: Results from the Interfant-99 Study. Blood 116:2644-2650, 2010
23. Childhood Acute Lymphoblastic Leukaemia Collaborative Group (CALLCG): Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: A systematic review and meta-analysis. Br J Haematol 145: 376-388, 2009
24. Eden T, Pieters R, Richards S, et al: Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia: An individual patient data meta-analysis involving 5,659 children. Br J Haematol 149:722-733, 2010
25. Escherich G, Richards S, Stork LC, et al: Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia. Leukemia 25:953-959, 2011
26. Richards S, Pui CH, Gayon P, et al: Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 60:185-195, 2013
27. Pieters R, Hunger SP, Boos J, et al: L-asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase. Cancer 117:238-249, 2011
28. Tong WH, Pieters R, Kaspers GJ, et al: A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood 123:2026-2033, 2014
29. Pui CH, Gaynon PS, Boyett JM, et al: Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 359:1909-1915, 2002
30. Pui CH, Chessells JM, Camitta B, et al: Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 17:700-706, 2003
31. Nachman JB, Heerema NA, Sather H, et al: Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110:1112-1115, 2007
32. Aricò M, Valsecchi MG, Camitta B, et al: Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 342:998-1006, 2000
33. Aricò M, Schrappe M, Hunger SP, et al: Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 28:4755-4761, 2010
34. Biondi A, Schrappe M, De Lorenzo P, et al: Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): A randomised, open-label, intergroup study. Lancet Oncol 13:936-945, 2012
35. Mullighan CG, Su X, Zhang J, et al: Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 360:470-480, 2009
36. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al: A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study. Lancet Oncol 10:125-134, 2009
37. Roberts KG, Li Y, Payne-Turner D, et al: Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 371:1005- 1015, 2014
38. Coustan-Smith E, Mullighan CG, Onciu M, et al: Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10:147-156, 2009
39. Buitenkamp TD, Izraeli S, Zimmermann M, et al: Acute lymphoblastic leukemia in children with Down syndrome: A retrospective analysis from the Ponte di Legno study group. Blood 123:70-77, 2014
40. Schrappe M, Hunger SP, Pui CH, et al: Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med 366:1371- 1381, 2012
41. Holmfeldt L, Wei L, Diaz-Flores E, et al: The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 45:242-252, 2013
42. Schultz KR, Carroll A, Heerema NA, et al: Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia 28:1467-1471, 2014
43. Zwaan CM, Rizzari C, Mechinaud F, et al: Dasatinib in children and adolescents with relapsed or refractory leukemia: Results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol 31:2460-2468, 2013
44. van der Veer A, Waanders E, Pieters R, et al: Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 122:2622-2629, 2013
45. Roberts KG, Pei D, Campana D, et al: Outcome of children with BCR-ABL1 - like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol 32:3012-3020, 2014
46. Patrick K, Wade R, Goulden N, et al: Outcome for children and young people with early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol 166:421-424, 2014
47. Bohnstedt C, Levinsen M, Rosthøj S, et al: Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia. Leukemia 27:866-870, 2013
48. Buitenkamp TD, Pieters R, Gallimore NE, et al: Outcome in children with Down's syndrome and acute lymphoblastic leukemia: Role of IKZF1 deletions and CRLF2 aberrations. Leukemia 26:2204- 2211, 2012
49. Mullighan CG, Collins-Underwood JR, Phillips LA, et al: Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet 41:1243-1246, 2009
50. Hertzberg L, Vendramini E, Ganmore I, et al: Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: A report from the International BFM Study Group. Blood 115:1006-1017, 2010
51. Mullighan CG: Genomic characterization of childhood acute lymphoblastic leukemia. Semin Hematol 50:314-324, 2013
52. Russell LJ, Capasso M, Vater I, et al: Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 114:2688-2698, 2009
53. Mullighan CG, Zhang J, Harvey RC, et al: JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 106:9414-9418, 2009
54. Roberts KG, Morin RD, Zhang J, et al: Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22:153-166, 2012
55. Weston BW, Hayden MA, Roberts KG, et al: Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol 31:e413-e416, 2013
56. Lengline E, Beldjord K, Dombret H, et al: Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica 98:e146-e148, 2013
57. Homminga I, Pieters R, Langerak AW, et al: Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell 19:484- 497, 2011
58. Zhang J, Ding L, Holmfeldt L, et al: The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481:157-163, 2012
59. Treanor LM, Zhou S, Janke L, et al: Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential. J Exp Med 211:701- 713, 2014
60. Shah S, Schrader KA, Waanders E, et al: A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet 45:1226-1231, 2013
61. Treviño LR, Yang W, French D, et al: Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet 41:1001-1005, 2009
62. Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al: Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet 41:1006-1010, 2009
63. Sherborne AL, Hosking FJ, Prasad RB, et al: Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet 42: 492-494, 2010
64. Xu H, Yang W, Perez-Andreu V, et al: Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst 105:733-742, 2013
65. Migliorini G, Fiege B, Hosking FJ, et al: Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. Blood 122:3298-3307, 2013
66. Ellinghaus E, Stanulla M, Richter G, et al: Identification of germline susceptibility loci in ETV6- RUNX1-rearranged childhood acute lymphoblastic leukemia. Leukemia 26:902-909, 2012
67. Perez-Andreu V, Roberts KG, Harvey RC, et al: Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. Nat Genet 45:1494-1498, 2013
68. Mullighan CG, Goorha S, Radtke I, et al: Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446:758-764, 2007
69. Wesolowska-Andersen A, Borst L, Dalgaard MD, et al: Genomic profiling of thousands of candidate polymorphisms predicts risk of relapse in 778 Danish and German childhood acute lymphoblastic leukemia patients. Leukemia 29:297-303, 2015
70. Holleman A, Cheok MH, den Boer ML, et al: Gene expression patterns in drug resistance acute lymphoblastic leukemia and response to treatment. N Engl J Med 351:533-542, 2004
71. Lugthart S, Cheok MH, den Boer ML, et al: Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 7:375-386, 2005
72. Sorich M, Pottier N, Pei D, et al: In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile. PLoS Med 5:e83, 2008
73. Yang JJ, Cheng C, Yang W, et al: Genomewide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301:393-403, 2009
74. Cheng Q, Yang W, Raimondi SC, et al: Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet 37:878-882, 2005
75. Treviño LR, Shimasaki N, Yang W, et al: Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 27:5972-5978, 2009
76. Diouf B, Cheng Q, Krynetskaia NF, et al: Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells. Nat Med 17:1298-1303, 2011
77. Ramsey LB, Bruun GH, Yang W, et al: Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 22:1-8, 2012
78. Gregers J, Christensen IJ, Dalhoff K, et al: The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood 115:4671-4677, 2010
79. Kager L, Cheok M, Yang W, et al: Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 115:110-117, 2005
80. Belkov VM, Krynetski EY, Schuetz JD, et al: Reduced folate carrier expression in acute lymphoblastic leukemia: A mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood 93:1643-1650, 1999
81. Fernandez CA, Smith C, Yang W, et al: HLA-DRB1∗07:01 is associated with a higher risk of asparaginase allergies. Blood 124:1266-1276, 2014
82. Ramsey LB, Panetta JC, Smith C, et al: Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 121:898-904, 2013
83. Lennard L, Lilleyman JS, Van Loon J, et al: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336:225-229, 1990
84. Stanulla M, Schaeffeler E, Flohr T, et al: Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 293: 1485-1489, 2005
85. Schmiegelow K, Forestier E, Kristinsson J, et al: Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: Results from the NOPHO ALL-92 study. Leukemia 23:557-564, 2009
86. Relling MV, Hancock ML, Rivera GK, et al: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001-2008, 1999
87. Evans WE, Hon YY, Bomgaars L, et al: Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 19:2293-2301, 2001
88. Yang JJ, Landier W, Yang W, et al: Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol 33:1235-1242, 2015
89. Diouf B, Crews KR, Lew G, et al: Association of an inherited genetic variant with vincristinerelated peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 313:815-823, 2015
90. Jones TS, Kaste SC, Liu W, et al: CRHR1 polymorphisms predict bone density in survivors of acute lymphoblastic leukemia. J Clin Oncol 26:3031-3037, 2008
91. Relling MV, Yang W, Das S, et al: Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 22: 3930-3936, 2004
92. French D, Hamilton LH, Mattano LA Jr, et al: A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 111:4496-4499, 2008
93. Bhojwani D, Sabin ND, Pei D, et al: Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol 32:949-959, 2014
94. Dumitrescu L, Brown-Gentry K, Goodloe R, et al: Evidence for age as a modifier of genetic associations for lipid levels. Ann Hum Genet 75:589- 597, 2011
95. Kawedia JD, Liu C, Pei D, et al: Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 119:1658-1664, 2012
96. Wang X, Liu W, Sun CL, et al: Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: A report from the Children's Oncology Group. J Clin Oncol 32:647-653, 2014
97. Yeoh AE, Tan D, Li CK, et al: Management of adult and paediatric acute lymphoblastic leukaemia in Asia: Resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncol 14: e508-e523, 2013
98. Stock W, La M, Sanford B, et al: What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 112:1646-1654, 2008
99. Boissel N, Auclerc MF, Lhéritier V, et al: Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21:774-780, 2003
100. Pui CH, Pei D, Campana D, et al: Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 29:386-391, 2011
101. Toft N, Birgens H, Abrahamsson J, et al: Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. Eur J Haematol 90:404-412, 2013